Like many countries in Eastern Europe and Central Asia, the HIV epidemic is largely driven by injecting drug use. But an active civil society in the Ukraine has had major success in turning around the epidemic among people who inject drugs.
In 2001, Indian generic drug manufacturer Cipla announces that it will sell a generic copy of a triple-therapy antiretroviral (ARV) for US $350 per patient per year. This has an incredible impact.
The years 2002-2008 see a significant increase in funding for the global HIV response from donor governments. However, since then funding has more or less flat-lined.
Average life expectancy across many parts of sub-Saharan Africa plummets as a result of the HIV epidemic. But after generics become available, countries start antiretroviral programmes which bring about improvements in life expectancy.
Average life expectancy across many parts of sub-Saharan Africa plummets as a result of the HIV epidemic. But after generics become available, countries start antiretroviral programmes which bring about improvements in life expectancy.
“We are threatened with extinction. People are dying in chillingly high numbers. It is a crisis of the first magnitude.”
- President Festus Mogae of Botswana.
